恩扎卢胺(Enzalutamide) - 药物靶点：AR_在研适应症：前列腺癌，去势敏感前列腺癌，HRR 基因突变去势抵抗性前列腺癌_专利_临床

A Phase II, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of the Combination of Inavolisib Plus Enzalutamide Versus Physician's Choice of ARPI or Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer

This study will evaluate the efficacy and safety of the combination of inavolisib plus enzalutamide compared with physician's choice of alternative androgen receptor pathway inhibitor (ARPi) or docetaxel in biomarker-selected participants with metastatic castrate-resistant prostate cancer (mCRPC) who have received one prior second-generation ARPi.

开始日期2026-03-31

申办/合作机构

Roche Holding AG

NCT06616155

/ Recruiting临床1/2期IIT

Study of JAK Inhibition in Stem-Like Prostate Cancer (JASPER): A Phase 1b/2a Multicenter Study of Ruxolitinib and Enzalutamide in Castration Resistant Prostate Cancer

This phase I/II tests the safety, side effects and best dose of ruxolitinib in combination with enzalutamide and how well it works in treating patients with prostate cancer that remains despite blocking hormone production (castration-resistant) and that has spread from where it first started to other places in the body (metastatic). Ruxolitinib, a kinase inhibitor, slows down the growth of the tumor by blocking the proteins, JAK1 and JAK2, tumors use to grow. Enzalutamide, an androgen receptor inhibitor, works by blocking the effects of androgen (a male reproductive hormone). This may help stop the growth and spread of tumor cells that need testosterone to grow. Giving ruxolitinib in combination with enzalutamide may be safe, tolerable, and/or effective in treating metastatic castration-resistant prostate cancer.

开始日期2026-01-30

申办/合作机构

Rogel Cancer Center: University of Michigan

[+1]

NCT07230106

/ Recruiting临床2期

A Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of HS-20093 or SHR2554 Tablets in Combination With Novel Hormonal Agents in Participants With Metastatic Prostate Cancer

This is a phase II, multicentre clinical study investigating HS-20093 or SHR2554 in combination with a Novel Hormonal Agent (NHA) for advanced prostate cancer. The trial comprises two cohorts.

开始日期2025-12-08

申办/合作机构

江苏恒瑞医药股份有限公司

100 项与恩扎卢胺相关的临床结果

登录后查看更多信息

100 项与恩扎卢胺相关的转化医学

登录后查看更多信息

100 项与恩扎卢胺相关的专利（医药）

登录后查看更多信息

3,883

项与恩扎卢胺相关的文献（医药）

2026-06-01·Health policy OPEN

Price transparency & out-of-pocket payments for medications: Implications of associated delivery fees in the United States

Article

作者: Kaye, Deborah R ; Scales, Charles D ; George, Daniel J ; Lee, Hui-Jie ; Bundorf, M Kate

Background:

Price transparency has been cited as a tool to reduce out-of-pocket (OOP) payments to patients. These tools for prescription drugs often focus on the price to patients for the drug alone. However, costs associated with drug delivery (i.e. infusion center fees, labs, etc) are often unknown and could impact the effectiveness of price transparency tools. Objective: To examine total OOP payments on day of drug receipt ("full day", i.e. drug + drug administration fees) out-of-pocket (OOP) payments associated with six first-line treatments for metastatic castrate resistant prostate cancer and compare these with payments for drug alone and by insurance type.

Methods:

Using the IBM Marketscan databases, we identify male patients who initiated treatment with one of six focus drugs (docetaxel, abiraterone, enzalutamide, sipuleucel-T, cabazitaxel, and radium-223) used to treat mCRPC from 07/01/2013-06/30/2019. We calculated total OOP payments on day of drug receipt (full day OOP payments) by drug type for six first line treatments. We then used a two-part model to assess the association of first-line therapy with OOP payments for the four most frequently prescribed during the study time period.

Results:

We find that there is variation in the proportion of payments for drug alone relative to full day payments across first-line treatments. However, regression-adjusted mean full day OOP payments are not statistically different across first-line treatments for mCRPC for the four most frequently prescribed drugs. There are differences in the likelihood that an individual will incur any OOP payment by first-line treatment type and by health plan type.

Conclusion:

These analyses suggest that when accounting for additional services required on the day of drug receipt, the amount a patient pays to receive a medication for mCRPC can be very different from the OOP payment for the drug alone; these payments also vary by drug and health plan type. Therefore, price transparency for drug alone may not lead to reduced OOP payments for patients.

2026-06-01·COMPUTATIONAL BIOLOGY AND CHEMISTRY

Boolean network-based identification of optimal drug combinations for prostate cancer

Article

作者: Datta, Aniruddha ; Kumar, Addanki Pratap ; Bhattacharjee, Pranabesh

Prostate cancer is one of the most common cancers among men in the United States and is a leading cause of cancer-related deaths and the second most common cancer in men worldwide. In this study, we used a Boolean network model to analyze prostate cancer signaling pathways and to identify optimal drug combinations for precision therapy. By integrating publicly available biological signaling pathway data with recent research findings, we developed a comprehensive model that represents protein-protein interactions, gene mutations, and pathway dysregulation. Faults induced by mutations were modeled using the "stuck at 0" or "stuck at 1" fault paradigms, capturing the impact of genetic alterations on pathway behavior. The model was simulated across various drug combinations to determine which therapies could most effectively alleviate the aberrant signaling caused by specific mutations. To quantify therapeutic efficacy, we calculated a Size Difference (SD) score, a metric analogous to Hamming distance, measuring the deviation from normal, for each drug combination and fault scenario. The results revealed that drug combinations involving Berberine, Docetaxel, Olaparib, and Enzalutamide showed promising prediction efficacy (more than 90 %), indicating higher therapeutic potential. A distinguishing feature of this work is that, in addition to the standard prostate cancer drugs, we have included Berberine, a non-toxic natural compound with beneficial effects. These computational findings provide a framework for future experimental and clinical validation, which is necessary to confirm the therapeutic relevance of the predicted drug combinations.

2026-05-01·CELLULAR SIGNALLING

The YAP1 and EPHA3 receptor tyrosine kinase axis regulates cellular plasticity and treatment response

Article

作者: Dwead, Abdulrahman M ; Cinar, Bekir ; Khazaw, Kezhan ; Al-Mathkour, Marwah M

The transcriptional coregulator YAP1 and the receptor tyrosine kinase EPHA3 regulate key cellular processes, including cell interactions, motility, survival, tissue development, carcinogenesis, and metastasis. Although their individual roles have been extensively studied, their cooperative functions remain poorly understood. Here, we investigated the relationship between EPHA3 and YAP1 in human prostate tumor tissues and cell models. Integrated transcriptomic and immunological analyses reveal a strong positive correlation between YAP1 and EPHA3 expression, which is significantly associated with tumor progression. EPHA3 knockout reduces cell proliferation and increases sensitivity to the androgen receptor inhibitor enzalutamide and the YAP1-TEAD inhibitor CA3 in vitro. EPHA3 depletion also reduces GTP-bound active RHOA and phosphorylated ERK levels and differentially affects epithelial-mesenchymal transition and cancer stem cell programs. In addition, EPHA3 silencing attenuates cell migration and invasion, an effect dependent on YAP1 activation. Bioinformatics analysis further indicates that high YAP1 and EPHA3 correlate with developmental and EMT-related gene signatures. These results demonstrate that the YAP1-EPHA3 axis is a key mediator of cell survival, plasticity, and tumor progression, and may serve as a promising cancer drug target.

1,672

项与恩扎卢胺相关的新闻（医药）

2026-04-01

·天然产物靶点发现

JACS/NCB（2篇）/APSB | 中山大学尹胜教授团队成果大戟来源天然产物活性及靶点研究

大戟科植物及其内生真菌富含结构多样的二萜类（如瑞香烷型、惕各烷型）、四氢蒽醌类等天然化合物，凭借其独特的“优势结构”，成为天然药物研发的核心资源库。然而，这类化合物的直接作用靶点不明确、作用机制模糊，长期以来是制约其向临床候选药物转化的关键瓶颈。中山大学药学院尹胜教授团队针对这一难题，采用基于活性的蛋白组分析方法（光亲和标记），通过对大戟科天然活性分子进行结构改造，引入点击化学、光亲和标记基团构建特异性探针，结合靶点垂钓、LC-MS/MS分析等技术，精准鉴定分子作用靶点并解析机制。成功在去势抵抗性前列腺癌（CRPC）、肝纤维化、非小细胞肺癌（NSCLC）疾病领域取得突破，不仅发现了强效活性分子，更鉴定出 3 个全新治疗靶点，为相关疾病的精准治疗开辟了新路径。 1. JACS（IF 15.6）| 发现高活性的瑞香烷型二萜类化合物靶向核转运蛋白importin-β1治疗去势抵抗型前列腺癌 2022年9月14日，中山大学药学院尹胜教授团队与王军舰教授团队合作在J. Am. Chem. Soc.发表题为“Discovery of Highly Potent Daphnane Diterpenoids Uncovers Importin-β1 as a Druggable Vulnerability in Castration-Resistant Prostate Cancer”的研究论文。该研究从结构多样性大戟科二萜库中筛选获得一个在体内外具有强效抗CRPC的瑞香烷型二萜小分子DD1，并通过多种手段发现和证实其直接作用靶点为核转运蛋白importin-β1，首次揭示了importin-1在CRPC进展中的功能及其作为药物靶点的可行性，为开发新型CRPC治疗药物提供了强效importin-1类抑制剂。研究人员对数年来积累的结构多样性大戟科二萜天然产物库（255个化合物，16类骨架）进行抗去势抵抗型前列腺癌（CRPC）活性筛选，发现了系列具有高活性的瑞香烷型二萜，其中化合物DD1活性最佳；DD1能够显著诱导CRPC细胞发生凋亡，减少细胞集落形成并抑制前列腺癌病人来源肿瘤类器官的生长。基于活性分子合成了光亲和探针在细胞内进行原位靶点垂钓，发现化合物潜在作用靶点为核转运蛋白importin-1；随后，利用竞争性结合pull-down实验、细胞热转移实验（CETSA）、挽救实验、荧光共定位、表面等离子共振（SPR）等实验进行了证实；截断株蛋白pull-down实验、光交联质谱分析及残基突变实验表明化合物主要作用于importin-β1蛋白C端550aa-876aa区域，其中Gln560、Phe577和Leu580是关键的结合氨基酸。利用蛋白组学和转录组学技术，发现化合物DD1通过抑制importin-β1影响了多种与CRPC进展密切相关的重要驱动因子（如AR、MYC、E2F1等）的核聚集，阻止了其下游信号网络，进而抑制了CRPC细胞的生长、增殖和存活。研究人员还通过对前列腺癌临床病人数据库调研及免疫组化实验分析，发现相比于正常或癌旁组织，importin-β1在前列腺癌组织中高表达，且与疾病分期、病人Gleason评分和转移程度均呈正相关关系，表明importin-β1与CRPC的发生发展密切相关，扮演着促癌因子的作用。最后，研究人员利用22Rv1细胞异种移植瘤和病人来源移植瘤（PDX）模型对DD1的体内抗肿瘤效应进行评价，结果显示化合物在低剂量（0.5 mg/kg）下能发挥强效的抗肿瘤作用，且对各脏器无明显影响。此外，研究人员发现在结合位点突变的异种移植瘤体内模型中，DD1抗肿瘤效果被大大削弱，进一步证实了化合物通过importin-β1发挥抗CRPC功效。综上所述，本研究证实了importin-β1作为抗CRPC新靶点的潜力，并为克服CRPC耐药的药物研发提供了天然先导分子。 https://pubs.acs.org/doi/10.1021/jacs.2c06449 2. APSB（IF 14.6）| 发现一种高效且可口服的importin-β1抑制剂，可克服晚期前列腺癌对恩杂鲁胺的耐药性 2023年7月24日，中山大学药学院尹胜教授团队与王军舰教授团队合作在APSB（IF 14.6）发表题为“Discovery of Highly Potent Daphnane Diterpenoids Uncovers Importin-β1 as a Druggable Vulnerability in Castration-Resistant Prostate Cancer”的研究论文。鉴于DD1 的治疗窗口狭窄（腹腔注射的 LD50 约为 4 毫克/千克），且口服生物利用度较差。我们对 DD1 进行了优化，生成了具有更好耐受性和口服生物利用度的改进型 Importin-β1 抑制剂 DD1-Br。DD1-Br 在体外和体内均显示出强大的抗前列腺癌转移效果，并能够克服恩杂鲁胺的耐药性。团队前期从结构多样性大戟科二萜小分子库中筛选获得一个在体内外具有强效抗CRPC的瑞香烷型二萜小分子DD1，并通过多种手段发现和证实其直接作用靶点为核转运蛋白importin-β1，首次揭示了importin-β1在CRPC进展中的功能及其作为药物靶点的可行性，为开发新型CRPC治疗药物提供了强效importin-β1类抑制剂。在本研究中，我们对天然的 importin-β1 抑制剂 DD1 进行了优化，得到了一种性能更优的类似物 DD1-Br，其具有更好的耐受性（超过 25 倍）和口服生物利用度。DD1-Br 能够以亚纳摩尔的效力抑制去势抵抗性前列腺癌（CRPC）细胞的存活，并在单药治疗（0.5 毫克/千克）和恩杂鲁胺联合治疗的耐药 CRPC 模型中完全阻止肿瘤生长。机制研究表明，通过靶向 importin-β1，DD1-Br 显著抑制了多种 CRPC 驱动因子（特别是 AR-V7，这是恩杂鲁胺耐药的主要因素）在细胞核中的积累，从而全面抑制了下游的致癌信号传导。这项研究为 CRPC 提供了有前景的候选药物，并展示了通过靶向 importin-β1 来克服晚期 CRPC 中的耐药性的潜力。 https://www.sciencedirect.com/science/article/pii/S2211383523002794?via%3Dihub 3.Nat Chem Biol | 狼毒大戟中一种二萜类天然产物靶向载脂蛋白L2（APOL2）减轻肝纤维化 2024年8月5日，中山大学药学院尹胜教授团队与附属第一医院郭剑平研究员团队合作在Nature Chemical Biology（IF 13.7）表了题为“A natural small molecule alleviates liver fibrosis by targeting apolipoprotein L2”的研究论文。以抗肝纤维化活性为导向，对大戟科二萜类化合物库进行了高内涵筛选，获得一个在体内外具有强效抗肝纤维化活性的惕各烷型二萜小分子DP，通过化学生物学手段发现和证实其直接作用靶点为Apolipoprotein L2（APOL2），并首次揭示了APOL2为治疗肝纤维化的潜在新靶点。为了从自然界中发现新的抗肝纤维化药物，构建了一个结构多样的大戟科二萜类化合物文库，并通过高内涵筛选评估了其抗肝纤维化的潜力。在一系列具有活性的tigliane二萜类化合物中，从大戟中提取的主要成分12-脱氧佛波13-棕榈酸酯(DP(1))被鉴定为活性最强的化合物。在此证明DP是一种有前景的抗肝纤维化药物，在体外和体内都比临床试验药物PFD更有效。机制上，DP直接靶向载脂蛋白L2 (APOL2)，然后损害其下游SERCA2-PERK-HES1轴，从而阻断TGF-β1诱导的hsc活化。DP是分离自Euphorbia fischeriana的主要成分。光亲和标记结合液相色谱-串联质谱(LC-MS /MS)鉴定APOL2是其直接靶点。原位和体外亲和力pulldown实验、细胞热位移实验(CETSA)、荧光探针DP- bod及截短株揭示DP与APOL2的MD 186 - 266 aa区相互作用，而N212和V216是负责结合的关键残基。 https://www.nature.com/articles/s41589-024-01704-3 4.Nat Chem Biol（IF 13.7）|中山大学尹胜教授团队大戟属植物内生真菌来源小分子靶向LIC1诱导自噬抗NSCLC 2025年10月16日，中山大学药学院尹胜教授团队在Nat Chem Biol（IF 13.7）发表题为“A small molecule targets LIC1 to suppress lung tumor growth by inducing autophagy”的文章。从植物大戟（Euphorbia wallichii）共生的真菌Malbranchea umbrina D16粗提物具有很强的抗nsclc活性。随后的分离和结构改造工作促成了抗 NSCLC 的先导化合物的开发。从机制上讲，该先导化合物直接作用于动力蛋白轻链 1（LIC1），有效地抑制了 LIC1 与RUVBL1之间的相互作用。这种抑制作用引发核糖体碰撞，并激活下游的 GCN2–eIF2α–ATF4 轴介导的综合应激反应（ISR），最终导致细胞自噬性死亡。我们的研究结果表明，LIC1 是非小细胞肺癌中的一个新治疗靶点，而该先导化合物作为强效的 LIC1 抑制剂，是治疗这种疾病的一种有前景的药物候选物。光亲和标记靶点鉴定技术我们从大戟内生真菌衍生的小分子化合物库中鉴定出了一个强效的自噬诱导剂——3,4-diisobutyryl derivative of auxarthrol A（DAA）。DAA 在非小细胞肺癌（NSCLC）肿瘤中表现出显著的抗肿瘤效果，并能增强抗 PD1 免疫疗法对肿瘤的敏感性。通过光亲和标记法，我们发现 light intermediate chain 1 （LIC1）是驱动蛋白的一个亚基，是 DAA 的直接靶点。我们发现 LIC1 在 NSCLC 肿瘤中过度表达，并与不良预后相关。从机制上讲，DAA 对 LIC1 的靶向作用显著破坏了 LIC1 与应激感知效应器 RuvB 样 AAA ATP 酶 1 之间的相互作用，进而增强了下游的 GCN2 - eIF2α - ATF4 轴介导的综合应激反应，最终促进自噬性细胞死亡。我们的研究结果将 LIC1 定义为 NSCLC 的一种新型治疗靶点，并强调了 DAA 作为这种疾病潜在的自噬诱导剂的潜力。 https://www.nature.com/articles/s41589-025-02040-w

2026-04-01

·EndPoints

Oric to advance prostate cancer drug to Phase 3, but combo choice raises doubts

Oric Pharmaceuticals on Tuesday detailed its plans to advance a PRC2 inhibitor into a registrational program for prostate cancer after sharing results from a Phase 1b trial. But the company’s shares $ORIC dropped by as much as 25% before market open Wednesday as investors had reservations about the biotech’s choice of androgen receptor inhibitor it will combine the investigational drug with. Oric said it plans to advance its candidate, known as rinzimetostat, and Bayer’s Nubeqa into a Phase 3 study. The trial will enroll 600 patients with metastatic castration-resistant prostate cancer (mCRPC) across more than 20 countries. It is set to start in the first half of this year. Jefferies analysts wrote Wednesday that the negative stock move might be due to onlookers thinking that Johnson & Johnson’s Erleada would have been a “better fit strategically” than Nubeqa. Results from a recent head-to-head real-world analysis show Erleada cut the risk of death by 51% compared with Nubeqa in certain prostate cancer patients, although they aren’t the same ones Oric is targeting. Oric’s early-phase trial recruited mCRPC patients who had a median two prior lines of therapy, including previous treatment with abiraterone. The analysts wrote that Oric decided to opt for Nubeqa because it has a lower risk of drug-drug interactions with the investigational drug compared with Erleada. Oric’s choice of combination approach was also based on data from the Phase 1b trial, which tested two different doses of rinzimetostat with Nubeqa, but also with Erleada. The Tuesday release did not report data with Erleada. Results from the Phase 1b trial also led to Oric choosing the lower dose (400 mg) of rinzimetostat versus a higher one (600 mg). The company said that the higher dose was associated with a “modestly higher rate of adverse events.” The most common side effects at the lower dose were fatigue, diarrhea and nausea. There were no grade 4 or 5 events associated with the regimen. The company added both doses had “comparable efficacy,” although the Tuesday data were not split by dose level. Of the 18 evaluable patients treated with the investigational combo of rinzimetostat and Nubeqa, 84% were still alive with no disease progression at five months with a median follow-up of 4.9 months. With the caveat of cross-trial comparison, the Tuesday data are “consistent with” the results attained by Pfizer’s candidate, called mevrometostat, in combination with Xtandi in a Phase 3 trial, despite Oric patients being more heavily pretreated, the Jefferies analysts said. Both rinzimetostat and mevrometostat inhibit the PRC2 complex, but via different subunits — rinzimetostat targets EED, while mevrometostat acts on EZH2. Editor’s note: This story was updated to clarify drug mechanisms.

临床3期临床1期临床2期临床终止临床结果

2026-04-01

·Firstwordpharma

ORIC details Phase III prostate cancer plans for PRC2 inhibitor

ORIC Pharmaceuticals said Tuesday it will start a registrational study this half for its experimental metastatic castration-resistant prostate cancer (mCRPC) treatment, rinzimetostat (formerly ORIC-944), as it looks to best a potential rival from Pfizer. The pharma is developing mevrometostat, an EZH2 inhibitor, also for mCRPR. Last year, Phase I data showed mevrometostat reduced the risk of progression or death by 49% when combined with Xtandi (enzalutamide) in patients with mCRPC, which analysts at the time called "very positive" for ORIC. The biotech's rinzimetostat is an allosteric inhibitor of PRC2, a chromatin modifying enzyme complex whose subunits include EZH2 and EED, the latter of which ORIC's compound binds to.While ORIC reported seemingly positive Phase Ib data for rinzimetostat to justify its move into Phase III testing, the company's shares plummeted 41% on Wednesday — though some investors questioned the drastic drop's rationale. "We’re not sure why the stock is selling off," Oppenheimer analysts wrote in a note. "The efficacy looks competitive to mevrometostat."ORIC said in a company release that the early efficacy data are "suggestive of meaningful and durable clinical benefit…compared to competitor data and historical outcomes with approved therapies."Survival and safety dataThe early-stage study evaluated 400-mg and 600-mg once-daily doses of rinzimetostat in combination with an AR inhibitor, either Johnson & Johnson's Nubeqa (darolutamide) or Bayer’s Erleada (apalutamide). An exposure-response analysis showed that the two dose levels had comparable efficacy, but it "identified statistically significant relationships between higher drug exposure and toxicities as well as increased rates of treatment modifications, clearly favouring the 400-mg dose on the basis of safety." As a result, ORIC has selected the 400-mg dose of rinzimetostat in combination with the standard, 600-mg twice daily dose of Nubeqa as the recommended Phase III dose. The drugmaker on Tuesday shared data from the 18 patients who received that specific cocktail in the Phase Ib trial.After a median follow-up of 4.9 months, patients achieved "landmark" radiographic progression-free survival (rPFS) rates of 93%, 84% and 84% at three, four and five months, respectively. According to ORIC, the results are consistent with data for mevrometostat in post-abiraterone mCRPC patients, and superior standard-of-care therapies.Additionally, in a subset of 15 patients with at least one post-baseline assessment as of the Jan. 16 cutoff, seven patients (47%) achieved a PSA50 response, with five (33%) confirmed responses. ORIC also evaluated molecular responses in 14 patients with detectable circulating tumour DNA (ctDNA) at baseline. In that group, 10 patients (71%) achieved a >50% ctDNA reduction.The findings "provide confirmatory evidence that support rinzimetostat’s potential best-in-disease clinical profile, reinforcing its path towards becoming a practice-changing therapy for patients with prostate cancer," said CEO Jacob M. Chacko in a company release, noting that the candidate demonstrated "a markedly cleaner safety profile than competitor regimens."The Oppenheimer analysts also homed in on the safety data, calling it "the real differentiator." "Most docs we’ve spoken to say mevrometostat has real tolerability issues, driven by diarrhoea and dysgeusia," they wrote. "Rinzimetostat chops those in half." ORIC reported that the most common treatment-released adverse events (TRAEs) in patients receiving the 400-mg dose of rinzimetostat were fatigue (39%), diarrhoea (22%) and nausea (22%). There was one case of a grade 3 TRAE, and no grade 4 or 5 AEs were linked to the treatment regimen. The company is planning to enrol 600 patients with mCRPC patients who were previously treated with abiraterone in the Phase III Himalayas-1 trial, comparing the rinzimetostat-Nubeqa duo against physician’s choice of an AR inhibitor or chemotherapy. The study's primary endpoint will be rPFS, with overall survival as the key secondary measure.

临床结果临床3期临床1期

100 项与恩扎卢胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10218	恩扎卢胺	L02BB04	DB08899

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
前列腺癌	韩国	Astellas Pharma Korea, Inc.	2024-12-03
去势敏感前列腺癌	美国	Astellas Pharma US, Inc.	2023-11-16
HRR 基因突变去势抵抗性前列腺癌	美国	Pfizer Inc.	2023-06-20
转移性前列腺癌	日本	Astellas Pharma, Inc.	2020-05-29
去势抵抗性前列腺癌	欧盟	Astellas Pharma Europe Ltd.	2013-06-21
去势抵抗性前列腺癌	冰岛	Astellas Pharma Europe Ltd.	2013-06-21
去势抵抗性前列腺癌	列支敦士登	Astellas Pharma Europe Ltd.	2013-06-21
去势抵抗性前列腺癌	挪威	Astellas Pharma Europe Ltd.	2013-06-21
激素依赖性前列腺癌	欧盟	Astellas Pharma Europe Ltd.	2013-06-21
激素依赖性前列腺癌	冰岛	Astellas Pharma Europe Ltd.	2013-06-21
激素依赖性前列腺癌	列支敦士登	Astellas Pharma Europe Ltd.	2013-06-21
激素依赖性前列腺癌	挪威	Astellas Pharma Europe Ltd.	2013-06-21
转移性去势抵抗性前列腺癌	美国	Astellas Pharma US, Inc.	2012-08-31

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期三阴性乳腺癌	临床3期	美国	Pfizer Inc.	2016-09-01
晚期三阴性乳腺癌	临床3期	美国	MediVation, Inc.	2016-09-01
晚期三阴性乳腺癌	临床3期	美国	Astellas Pharma, Inc.	2016-09-01
前列腺腺癌	临床3期	美国	Astellas Pharma US, Inc.	2014-01-22
前列腺腺癌	临床3期	美国	MediVation, Inc.	2014-01-22
前列腺腺癌	临床3期	加拿大	Astellas Pharma US, Inc.	2014-01-22
前列腺腺癌	临床3期	加拿大	MediVation, Inc.	2014-01-22
复发性前列腺癌	临床3期	美国	Astellas Pharma US, Inc.	2014-01-22
复发性前列腺癌	临床3期	美国	MediVation, Inc.	2014-01-22
复发性前列腺癌	临床3期	加拿大	Astellas Pharma US, Inc.	2014-01-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02194842 (PEACE-3 \| EORTC1333, ASCO_GU2026 \| BusinessWire) 人工标引	临床3期	转移性去势抵抗性前列腺癌	446	Enzalutamide + Radium-223	餘衊選構蓋憲顧製鏇築(艱鬱壓選獵鑰遞鬱顧鹽) = 衊鑰鹹遞醖憲願憲壓夢網鏇鹽顧淵衊餘醖網獵 (膚餘蓋獵鹽鹹鹹憲糧艱 ) 更多	积极	2026-02-26
				Enzalutamide	餘衊選構蓋憲顧製鏇築(艱鬱壓選獵鑰遞鬱顧鹽) = 壓顧窪膚選簾觸齋鏇醖網鏇鹽顧淵衊餘醖網獵 (膚餘蓋獵鹽鹹鹹憲糧艱 ) 更多
NCT03809000 (RTOG 3506 (STEEL), ASCO_GU2026)	临床2期	前列腺癌	188	LHRH analog + Enzalutamide 160 mg	廠夢觸蓋衊觸繭餘鑰築(醖鑰鹹鑰網鏇鏇襯鏇淵): HR = 0.62 (80.0% CI, 0.42 ~ 0.91), P-Value = 0.052	积极	2026-02-26
				LHRH analog
ASCO_GU2026	N/A	转移性去势敏感性前列腺癌 FOXA1 \| DUOXA1 \| BIRC5	76	ADT plus enzalutamide	遞壓憲築膚壓繭衊齋醖(鹽鏇艱範遞簾壓鏇鏇餘) = 鏇鏇糧簾簾範簾齋鑰築製憲築範壓觸鬱糧餘繭 (遞廠醖觸遞選淵窪夢遞 )	积极	2026-02-26
NCT06096870 (ASCO_GU2026)	临床2期	非转移性前列腺癌	50	Enzalutamide	製衊衊壓鹹艱積襯簾願(選壓簾鬱廠餘願遞壓製) = 鬱製顧網構艱簾選遞繭窪構蓋製築窪齋遞鏇淵 (餘壓糧積襯衊網窪鏇築, -81 ~ -100) 更多	积极	2026-02-26
NCT02319837 (EMBARK, ASCO_GU2026)	临床3期	-	1,061	Enzalutamide + Leuprolide	構築選膚願艱齋淵積襯(窪衊鑰艱淵餘鏇製觸衊) = 選餘網艱窪醖鹹艱齋夢壓獵醖鑰蓋膚遞積願鬱 (獵艱餘獵鹹齋壓糧遞製 ) 更多	积极	2026-02-26
				Leuprolide	構築選膚願艱齋淵積襯(窪衊鑰艱淵餘鏇製觸衊) = 選鹽網獵製衊鬱繭膚範壓獵醖鑰蓋膚遞積願鬱 (獵艱餘獵鹹齋壓糧遞製 ) 更多
NCT02286921 (TRANSFORMER, ASCO_GU2026)	临床3期	转移性去势抵抗性前列腺癌	157	Enzalutamide	構築鹽繭製觸餘鹽積築(繭夢醖淵鏇鹹廠鬱選鬱) = 糧餘糧淵繭廠願鏇憲醖積願願簾構齋顧襯鬱簾 (願積鏇襯選廠獵獵築壓 ) 更多	不佳	2026-02-26
				Bipolar Androgen Therapy (BAT)	構築鹽繭製觸餘鹽積築(繭夢醖淵鏇鹹廠鬱選鬱) = 糧構糧願齋鑰顧鬱築構積願願簾構齋顧襯鬱簾 (願積鏇襯選廠獵獵築壓 ) 更多
NCT05726292 (ASCO_GU2026)	临床2期	局限性前列腺癌新辅助	90	LHRH agonist/antagonist + Enzalutamide + Relacorilant	醖膚築鏇鏇製襯醖鑰鏇(壓獵鑰壓廠網衊簾壓膚): P-Value = 0.15 更多	积极	2026-02-26
				LHRH agonist/antagonist + Enzalutamide + Placebo
ASCO_GU2026	N/A	转移性去势敏感性前列腺癌一线	1,274	Enzalutamide	艱廠艱廠夢觸窪顧繭衊(構築餘醖鏇鏇餘窪構遞) = 遞積鹽窪壓鬱膚願蓋齋鑰憲鑰網鏇窪積蓋鬱鹽 (製顧選廠壓蓋艱夢製艱, NE ~ NE) 更多	积极	2026-02-26
				Apalutamide	艱廠艱廠夢觸窪顧繭衊(構築餘醖鏇鏇餘窪構遞) = 鹽築鏇願餘網淵簾憲製鑰憲鑰網鏇窪積蓋鬱鹽 (製顧選廠壓蓋艱夢製艱, NE ~ NE) 更多
ASCO_GU2026	N/A	转移性去势敏感性前列腺癌	4,806	Abiraterone acetate (mCSPC)	簾鬱醖顧齋製糧選範艱(襯構範鏇鬱繭窪繭遞繭) = Fatigue (31% ABI vs 34% ENZ) and falls (7% vs 8%) were slightly more common with ENZ, while hypertension was marginally higher in the ABI group (2% vs 1.8%). 積憲積製鹽簾觸構憲鑰 (齋繭選餘選窪艱構夢範 ) 更多	积极	2026-02-26
				Enzalutamide (mCSPC)
ASCO_GU2026	N/A	转移性前列腺癌	344	Enzalutamide (Charlson Comorbidity Index ≥3)	餘膚窪廠膚築齋獵淵齋(製衊鏇艱餘遞鬱獵衊顧) = 衊淵襯築夢襯顧鹽觸衊顧觸鬱鑰餘膚鏇繭糧構 (廠鏇觸艱簾築觸鑰艱觸, 25.9 ~ 55.1) 更多	积极	2026-02-26
				Abiraterone (Charlson Comorbidity Index ≥3)	餘膚窪廠膚築齋獵淵齋(遞襯網鏇簾憲範憲醖遞) = 願構廠糧齋餘衊觸襯餘繭範憲網範艱獵範鑰鹹 (壓遞蓋觸淵鬱遞糧築襯 )